Ronald Bentsur
Chief Executive Officer at NUVECTIS PHARMA, INC.
Net worth: 27 M $ as of 2024-03-30
Profile
Ronald E.
Bentsur is the founder and currently holds the position of Chairman, President & Chief Executive Officer at Nuvectis Pharma, Inc. which was founded in 2020.
He is also currently the Chairman at Ait Ltd., Independent Director at Beyond Air, Inc., Director at Beyond Air Ltd., and Venture Advisor at Israel Biotech Fund.
In the past, Mr. Bentsur served as the Chief Executive Officer & Director at Keryx Biopharmaceuticals, Inc. from 2009 to 2015, Chief Executive Officer at XTL Biopharmaceuticals Ltd.
from 2006 to 2009, Chief Executive Officer & Director at UroGen Pharma Ltd.
from 2015 to 2019, Director at Stemline Therapeutics, Inc. from 2009 to 2020, and Director-Technology Investment Banking at Leumi Partners Underwriters Ltd.
from 1998 to 2000.
He also held the position of Chief Financial Officer & Vice President-Finance at Keryx Biopharmaceuticals, Inc. from 2000 to 2006.
Mr. Bentsur's education includes an undergraduate degree from The Hebrew University of Jerusalem and an MBA from The Leonard N Stern School of Business.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
NUVECTIS PHARMA, INC.
18.25% | 2024-03-17 | 3,242,484 ( 18.25% ) | 27 M $ | 2024-03-30 |
BEYOND AIR, INC.
0.40% | 2024-03-19 | 144,736 ( 0.40% ) | 251 841 $ | 2024-03-30 |
Ronald Bentsur active positions
Companies | Position | Start |
---|---|---|
NUVECTIS PHARMA, INC. | Chief Executive Officer | 2020-07-26 |
BEYOND AIR, INC. | Director/Board Member | 2015-07-31 |
Beyond Air Ltd.
Beyond Air Ltd. BiotechnologyHealth Technology Beyond Air, Ltd. is a clinical-stage medical device and biopharmaceutical company engaging in the development of nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases. The company was founded by Yossef Av-Gay, Amir Avniel, and David Greenberg in May 2011 and is headquartered in Rehovot, Israel. | Director/Board Member | 2016-12-31 |
Ait Ltd.
Ait Ltd. BiotechnologyHealth Technology Ait Ltd. engages in research and development in biotechnology. The private company is located in Israel. The Israeli company was founded by Yossef Av-Gay, Amir Avniel, Avishai Abrahami. Amir Avniel has been the CEO of the company since 2011. | Chairman | 2015-07-31 |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Consultant / Advisor | - |
Former positions of Ronald Bentsur
Companies | Position | End |
---|---|---|
STEMLINE THERAPEUTICS, INC. | Director/Board Member | 2020-05-31 |
UROGEN PHARMA LTD. | Chief Executive Officer | 2019-01-02 |
KERYX BIOPHARMACEUTICALS | Chief Executive Officer | 2015-04-29 |
XTL BIOPHARMACEUTICALS LTD. | Chief Executive Officer | 2009-03-31 |
░░░░░ ░░░░░░░░░░░░░░░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Ronald Bentsur
The Hebrew University of Jerusalem | Undergraduate Degree |
The Leonard N Stern School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 5 |
---|---|
XTL BIOPHARMACEUTICALS LTD. | Health Technology |
NEXTGEN BIOMED LTD | Health Technology |
UROGEN PHARMA LTD. | Health Technology |
BEYOND AIR, INC. | Health Technology |
NUVECTIS PHARMA, INC. | Health Technology |
Private companies | 6 |
---|---|
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Leumi Partners Underwriters Ltd. | |
Beyond Air Ltd.
Beyond Air Ltd. BiotechnologyHealth Technology Beyond Air, Ltd. is a clinical-stage medical device and biopharmaceutical company engaging in the development of nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases. The company was founded by Yossef Av-Gay, Amir Avniel, and David Greenberg in May 2011 and is headquartered in Rehovot, Israel. | Health Technology |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Finance |
Ait Ltd.
Ait Ltd. BiotechnologyHealth Technology Ait Ltd. engages in research and development in biotechnology. The private company is located in Israel. The Israeli company was founded by Yossef Av-Gay, Amir Avniel, Avishai Abrahami. Amir Avniel has been the CEO of the company since 2011. | Health Technology |
- Stock Market
- Insiders
- Ronald Bentsur